David Ludlow, MD
Urology · Las Vegas, NVNPI 1932336039
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.8%), education and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Intuitive Surgical at 42.7% of the total. Reporting peaked in 2021 at $3,898 and has fallen 69.2% since, to $1,201 in 2025.
Across 155 payments — averaging $55.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Procept Biorobotics Corporation$1K
- Sumitomo Pharma America, Inc.$498
- Boston Scientific$400
- Telix Pharmaceuticals$373
- Coloplast$320
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$1251%
- Travel & lodging$90310%
- Food & beverage$4,57053%
- Education$3,00035%
- Gifts$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $3,698 |
| Procept Biorobotics Corporation | 12 | $1,138 |
| Sumitomo Pharma America, Inc. | 18 | $498 |
| Boston Scientific | 11 | $400 |
| Telix Pharmaceuticals | 11 | $373 |
| Coloplast | 11 | $320 |
| Dendreon Pharmaceuticals LLC | 9 | $273 |
| AbbVie | 7 | $270 |
| Astellas Pharma US Inc | 14 | $253 |
| Axonics, Inc. | 3 | $172 |
| Endo Pharmaceuticals Inc. | 8 | $152 |
| Urogen Pharma, Inc. | 5 | $129 |
| Urovant Sciences Inc | 1 | $125 |
| Myovant Sciences Inc. | 1 | $125 |
| Endo USA, Inc. | 5 | $117 |
| 180 Medical, Inc. | 3 | $68 |
| Accord Healthcare, Inc. | 3 | $64 |
| Merck | 2 | $62 |
| Johnson & Johnson(2 entities) | 3 | $53 |
| Pfizer | 2 | $47 |
| Immunitybio, Inc. | 2 | $47 |
| Bayer | 2 | $41 |
| Calyxo, Inc. | 1 | $38 |
| LSI Solutions Inc | 1 | $35 |
| Olympus America Inc. | 2 | $29 |
| Teleflex LLC | 1 | $27 |
| Laborie Medical Technologies Corp. | 1 | $26 |
| Photocure Inc | 1 | $16 |
| Tolmar, Inc. | 1 | $15 |
| Blue Earth Diagnostics | 1 | $15 |
| Antares Pharma, Inc. | 1 | $13 |
| Smith+Nephew | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,410
- AquaBeam Robotic System$769
- GEMTESA$250
- LithoVue$173
- Axonics$126
- ORGOVYX$125
- Lupron Depot$122
- AQUABEAM SYSTEM$115
How this compares
$8,652 in reported general payments places this provider in the 60th percentile of 63 urology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 164 | $147,843 |
| ElmironPentosan Polysulfate Sodium | 13 | $13,214 |
| MyrbetriqMirabegron | 12 | $9,660 |
| Tamsulosin Hcl | 321 | $4,098 |
| Silodosin | 26 | $1,858 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 92 | $1,538 |
| Solifenacin Succinate | 53 | $1,447 |
| Methenamine Hippurate | 18 | $1,304 |
| Tadalafil | 15 | $1,032 |
| Finasteride | 44 | $456 |
| Testosterone Cypionate | 16 | $267 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 93 | $260 |
| Ciprofloxacin Hcl | 53 | $244 |
| Ibuprofen | 72 | $219 |
| Tramadol Hcl | 11 | $15 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $498 | $147,843164 claims |
| Astellas Pharma US IncMyrbetriq | $253 | $9,66012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 63 urology providers in Nevada.
Other urology in Las Vegas
- Vijay GoliLas Vegas$105K
- Joel AbbottLas Vegas$69K
- Victor GrigorievLas Vegas$59K
- Omid LesaniLas Vegas$27K
- Joseph CandelaLas Vegas$24K
- Lawrence NewmanLas Vegas$22K
- Michael VerniLas Vegas$16K
- Mulugeta KassahunLas Vegas$13K
- Jason ZommickLas Vegas$12K
- Ilya GorbachinskyLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.